CN105431134A - 复合物 - Google Patents

复合物 Download PDF

Info

Publication number
CN105431134A
CN105431134A CN201480033617.1A CN201480033617A CN105431134A CN 105431134 A CN105431134 A CN 105431134A CN 201480033617 A CN201480033617 A CN 201480033617A CN 105431134 A CN105431134 A CN 105431134A
Authority
CN
China
Prior art keywords
mk2i
peptide
polymer
active agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480033617.1A
Other languages
English (en)
Chinese (zh)
Inventor
杜瓦·克雷格
埃文斯·布莱恩·康纳
布罗菲·科伦
霍金·凯尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CN105431134A publication Critical patent/CN105431134A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
CN201480033617.1A 2013-04-11 2014-04-11 复合物 Pending CN105431134A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811078P 2013-04-11 2013-04-11
USUS61/811078 2013-04-11
PCT/US2014/033873 WO2014169256A2 (en) 2013-04-11 2014-04-11 Polyplexes

Publications (1)

Publication Number Publication Date
CN105431134A true CN105431134A (zh) 2016-03-23

Family

ID=51690135

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480033617.1A Pending CN105431134A (zh) 2013-04-11 2014-04-11 复合物

Country Status (12)

Country Link
US (1) US10835549B2 (https=)
EP (1) EP2991616A4 (https=)
JP (1) JP2016518358A (https=)
KR (1) KR20150143639A (https=)
CN (1) CN105431134A (https=)
AU (1) AU2014250830A1 (https=)
BR (1) BR112015025968A2 (https=)
CA (1) CA2911315A1 (https=)
HK (1) HK1216152A1 (https=)
MX (1) MX2015014354A (https=)
RU (1) RU2015148055A (https=)
WO (1) WO2014169256A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3242886A4 (en) 2015-01-08 2018-08-29 Moerae Matrix, Inc., Formulation of mk2 inhibitor peptides
CN104815333B (zh) * 2015-04-05 2017-10-31 北京工业大学 一种聚离子胶束纳米粒子的制备方法及其应用
US11147827B2 (en) 2016-08-05 2021-10-19 Vanderbilt University Conjugation of lipophilic albumin-binding moiety to RNA for improved carrier-free in vivo pharmacokinetics and gene silencing

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535388A (ja) * 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
WO2003070823A2 (en) * 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
US9271933B2 (en) * 2007-11-27 2016-03-01 Rutgers, The State University Of New Jersey Graft copolymer polyelectrolyte complexes for drug delivery
US20110060123A1 (en) * 2008-04-30 2011-03-10 Kazunori Kataoka Charge conversional ternary polyplex
US20100150952A1 (en) * 2008-11-07 2010-06-17 University Of Washington pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY
CA2744104C (en) * 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US20130115256A1 (en) * 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
CN115957297A (zh) 2013-03-15 2023-04-14 节奏制药公司 药物组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KSHITIJ GUPTA ETAL: "Nanoparticle formation from poly(acrylicacid) and oppositely charged peptides", 《BIOPHYSICAL CHEMISTRY》 *
KSHITIJ GUPTA ETAL: "Nanoparticles of cationic chimeric peptide and sodium polyacrylate exhibit striking antinociception activity at lower dose", 《JOURNAL OF CONTROLLED RELEASE》 *

Also Published As

Publication number Publication date
RU2015148055A (ru) 2017-05-16
US20160058876A1 (en) 2016-03-03
CA2911315A1 (en) 2014-10-16
EP2991616A2 (en) 2016-03-09
WO2014169256A2 (en) 2014-10-16
KR20150143639A (ko) 2015-12-23
BR112015025968A2 (pt) 2018-01-09
EP2991616A4 (en) 2016-11-09
AU2014250830A1 (en) 2015-11-12
HK1216152A1 (zh) 2016-10-21
US10835549B2 (en) 2020-11-17
JP2016518358A (ja) 2016-06-23
MX2015014354A (es) 2016-06-07
WO2014169256A3 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
Gao et al. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics
Zhao et al. Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine (R15) triblock copolymer for siRNA delivery
Schellinger et al. Melittin-grafted HPMA-oligolysine based copolymers for gene delivery
Qiu et al. IL-17A injury to retinal ganglion cells is mediated by retinal Müller cells in diabetic retinopathy
Kim et al. Spatiotemporal control of neutrophil fate to tune inflammation and repair for myocardial infarction therapy
Wang et al. Lacritin-mediated regeneration of the corneal epithelia by protein polymer nanoparticles
Luo et al. Acid-activated melittin for targeted and safe antitumor therapy
JP6141517B2 (ja) 脂肪細胞標的非ウイルス性遺伝子伝達体
Sylvestre et al. Replacement of L-amino acid peptides with D-amino acid peptides mitigates anti-PEG antibody generation against polymer-peptide conjugates in mice
Herrera Estrada et al. Bioengineering bacterially derived immunomodulants: A therapeutic approach to inflammatory bowel disease
US11292878B2 (en) Poly(L-lysine isolphthalamide) (PLP) polymers with hydrophobic pendant chains
US9566347B2 (en) Peptides and methods using same
Wu et al. The antioxidant effect of tetrahedral framework nucleic acid‐based delivery of small activating RNA targeting DJ‐1 on retinal oxidative stress injury
WO2019028469A1 (en) FUNCTIONALIZED POLYMER MITOCHONDRIAL COMPOSITIONS AND METHODS OF USE IN CELL TRANSPLANTATION AND FOR MODIFYING METABOLIC PHENOTYPE
CN105431134A (zh) 复合物
US20220226499A1 (en) Metabolite Delivery for Modulating Metabolic Pathways of Cells
Bang et al. Targeted delivery of self-assembled nanocomplex between fusion peptides and siRNAs for breast cancer treatment
Okada Targeted siRNA therapy using cytoplasm-responsive nanocarriers and cell-penetrating peptides
Yanamadala Peptide carriers to improve uptake and functionality and to cross BBB to arrest secondary injury post TBI
Zou et al. Function of orthologous fibroblast growth factor 11 protein in angiogenesis and immunomodulatory after spinal cord injury
Xie et al. Overcoming intranasal delivery barriers with ultrastable polyzwitterionic siRNA nanocages for enhanced glioblastoma therapy
KR102004033B1 (ko) 엔도솜 분해능과 핵 내 전달능을 갖는 아스코르브산 2-인산(ascorbic acid 2-phosphate)과 이의 고분자 및 이들의 용도
WO2024026444A1 (en) Methods and compositions for using leucine zippers for crosslinking of cells and drug carriers
CN118580501A (zh) 一种抗纤维化的化合物
Lee et al. Angiogenesis of Human Adipose-Derived Stem Cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160323

WD01 Invention patent application deemed withdrawn after publication